letrozole has been researched along with Benign Neoplasms in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer." | 5.27 | Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. ( Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM, 2018) |
| " As an example, STEPP methodology is used to explore patterns of treatment effect for varying levels of the biomarker Ki-67 in the BIG (Breast International Group) 1-98 randomized clinical trial comparing letrozole with tamoxifen as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer." | 3.76 | Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. ( Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA, 2010) |
| "One hundred and nineteen women with cancer undergoing oocytes retrieval for fertility preservation were recruited." | 3.11 | Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation. ( Ciaffaglione, M; Cuce', V; Dallagiovanna, C; Filippi, F; Fustinoni, S; Pinna, M; Polledri, E; Reschini, M; Somigliana, E, 2022) |
| "The letrozole dose was fixed at 2." | 2.73 | A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. ( Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK, 2008) |
| "In women with cancer undergoing FP, letrozole appears to enhance response to ovarian stimulation while the presence of BRCA mutations is associated with lower oocyte and embryo yield." | 1.48 | Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes. ( Bedoschi, G; Emirdar, V; Moy, F; Oktay, K; Turan, V, 2018) |
| "Obesity is a risk factor for breast cancer progression." | 1.42 | A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors. ( Goloubeva, O; McLenithan, J; Sabnis, G; Schech, A; Yu, S, 2015) |
| "With improvement in cancer survival rates, there has been a shift in attention toward management of long-term consequences of cancer therapy, including infertility." | 1.39 | Response to ovarian stimulation in patients facing gonadotoxic therapy. ( Dillon, KE; Dokras, A; Efymow, BL; Gracia, CR; Johnson, LN; Mainigi, MA; Sammel, MD, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Dallagiovanna, C | 1 |
| Reschini, M | 1 |
| Polledri, E | 1 |
| Pinna, M | 1 |
| Ciaffaglione, M | 1 |
| Cuce', V | 1 |
| Somigliana, E | 1 |
| Fustinoni, S | 1 |
| Filippi, F | 1 |
| Goldrat, O | 1 |
| De Cooman, M | 1 |
| Mailliez, A | 1 |
| Delbaere, A | 1 |
| D'Orazio, E | 1 |
| Demeestere, I | 1 |
| Decanter, C | 1 |
| Kim, SW | 1 |
| Han, SJ | 1 |
| Han, JY | 1 |
| Kim, H | 1 |
| Ku, SY | 1 |
| Suh, CS | 2 |
| Turan, V | 1 |
| Bedoschi, G | 1 |
| Emirdar, V | 1 |
| Moy, F | 1 |
| Oktay, K | 2 |
| Plummer, R | 1 |
| Verheul, HM | 1 |
| De Vos, FYFL | 1 |
| Leunen, K | 1 |
| Molife, LR | 1 |
| Rolfo, C | 1 |
| Grundtvig-Sørensen, P | 1 |
| De Grève, J | 1 |
| Rottey, S | 1 |
| Jerusalem, G | 1 |
| Italiano, A | 1 |
| Spicer, J | 1 |
| Dirix, L | 1 |
| Goessl, C | 1 |
| Birkett, J | 1 |
| Spencer, S | 1 |
| Learoyd, M | 1 |
| Bailey, C | 1 |
| Dean, E | 1 |
| Johnson, LN | 1 |
| Dillon, KE | 1 |
| Sammel, MD | 1 |
| Efymow, BL | 1 |
| Mainigi, MA | 1 |
| Dokras, A | 1 |
| Gracia, CR | 1 |
| Kasum, M | 1 |
| Šimunić, V | 1 |
| Orešković, S | 1 |
| Beketić-Orešković, L | 1 |
| Kim, JH | 1 |
| Kim, SK | 1 |
| Lee, HJ | 1 |
| Lee, JR | 1 |
| Jee, BC | 1 |
| Kim, SH | 1 |
| Cakmak, H | 1 |
| Rosen, MP | 1 |
| Schech, A | 1 |
| Yu, S | 1 |
| Goloubeva, O | 1 |
| McLenithan, J | 1 |
| Sabnis, G | 1 |
| Domingo, J | 1 |
| Garcia-Velasco, JA | 1 |
| Chu, QS | 1 |
| Cianfrocca, ME | 1 |
| Goldstein, LJ | 1 |
| Gale, M | 1 |
| Murray, N | 1 |
| Loftiss, J | 1 |
| Arya, N | 1 |
| Koch, KM | 1 |
| Pandite, L | 1 |
| Fleming, RA | 1 |
| Paul, E | 1 |
| Rowinsky, EK | 1 |
| Rodriguez-Wallberg, K | 1 |
| Schover, L | 1 |
| Gheita, TA | 1 |
| Ezzat, Y | 1 |
| Sayed, S | 1 |
| El-Mardenly, G | 1 |
| Hammam, W | 1 |
| Lazar, AA | 1 |
| Cole, BF | 1 |
| Bonetti, M | 1 |
| Gelber, RD | 1 |
| Oktay, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect [NCT02093351] | Phase 1 | 79 participants (Actual) | Interventional | 2014-09-01 | Completed | ||
| Double Ovarian Stimulation in Cases of Preimplantation Genetic Testing: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore[NCT03291821] | 136 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 55.49 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 44.33 |
Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 9.490 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 8.256 |
Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 61.77 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 67.82 |
Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 10.05 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 10.48 |
Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 696.8 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 582.5 |
Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | micrograms per millilitre (mcg/mL) (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 40.98 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 35.83 |
Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 2292 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 2167 |
Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 118.9 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 111.8 |
Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 62.12 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 42.27 |
Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 9.456 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 7.216 |
Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | microgram x hour/millilitre (mcg*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 2751 | 2955 | 115.8 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 2233 | 3189 | 119.3 |
Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 154.2 | 149.1 | 5.727 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 130.3 | 162.9 | 5.923 |
2 reviews available for letrozole and Benign Neoplasms
| Article | Year |
|---|---|
Random-start ovarian stimulation in patients with cancer.
Topics: Adult; Aromatase Inhibitors; Chorionic Gonadotropin; Cryopreservation; Female; Fertility Preservatio | 2015 |
Oocyte cryopreservation for fertility preservation in women with cancer.
Topics: Cryopreservation; Estradiol; Female; Fertility Preservation; Humans; Infertility, Female; Letrozole; | 2016 |
3 trials available for letrozole and Benign Neoplasms
| Article | Year |
|---|---|
Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation.
Topics: Cryopreservation; Estradiol; Female; Follicular Fluid; Humans; Letrozole; Neoplasms; Oocytes; Ovulat | 2022 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Fem | 2008 |
11 other studies available for letrozole and Benign Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
Topics: Cryopreservation; Estradiol; Female; Fertility Preservation; Humans; Letrozole; Neoplasms; Ovulation | 2022 |
Predictor for supraphysiologic serum estradiol elevation on hCG triggering day of controlled ovarian stimulation using letrozole and gonadotropins in women with estrogen-dependent cancers.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Estrogens; Female; Gonadotropins; Humans; Letrozole; Monit | 2020 |
Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
Topics: Adult; Aromatase Inhibitors; BRCA1 Protein; Cryopreservation; Female; Fertility Preservation; Fertil | 2018 |
Response to ovarian stimulation in patients facing gonadotoxic therapy.
Topics: Adult; Antineoplastic Agents; Female; Fertility Preservation; Fertilization in Vitro; Gonadotropins; | 2013 |
Fertility preservation with ovarian stimulation protocols prior to cancer treatment.
Topics: Aromatase Inhibitors; Estrogen Antagonists; Female; Fertility Preservation; Gonadotropins; Humans; L | 2014 |
Efficacy of random-start controlled ovarian stimulation in cancer patients.
Topics: Cryopreservation; Estradiol; Female; Fertility Preservation; Fertilization in Vitro; Humans; Inferti | 2015 |
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Blood Glucose; Cell | 2015 |
Preservation of fertility in patients with cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fertility; Humans; Letrozole | 2009 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole | 2010 |
Options for preservation of fertility in women.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Em | 2005 |